-
公开(公告)号：US20200148737A1
公开(公告)日：2020-05-14
申请号：US16561587
申请日：2019-11-15
IPC分类号： C07K14/55 , C07K16/28 , C07K16/30 , C07K14/54 , A61P35/02 , A61P35/00 , C12N5/0783 , C07K16/24 , C07K16/10
摘要： This disclosure describes engineered compounds that engage NK cells and methods of using the compounds. Generally, the compound includes an NK engaging domain, a targeting domain that selectively binds to a target cell, and an NK activating domain operably linking the NK engaging domain and the targeting domain.
-
公开(公告)号：US20200129553A1
公开(公告)日：2020-04-30
申请号：US16529251
申请日：2019-08-01
申请人： NANTKWEST, INC.
IPC分类号： A61K35/17 , C07K16/28 , C07K14/735 , C07K14/55 , C07K14/54 , C07K14/725 , A61P35/00 , A61P35/04 , A61K9/00
摘要： Provided herein are compositions of NK-92® cells that express a CD19 CAR, CD16 and IL2, and the method of using these cells to and treat cancer in a patient.
-
公开(公告)号：US10604576B2
公开(公告)日：2020-03-31
申请号：US15480525
申请日：2017-04-06
申请人： Kymab Limited
发明人： Jamie Campbell , Nikole Sandy Nee Waddell , Stephen D. Gillies , Volker Germaschewski , Cassandra van Krinks , Ian Kirby , Miha Kosmac , Steve Arkinstall , Thomas Gallagher
摘要： The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
-
公开(公告)号：US20200093863A1
公开(公告)日：2020-03-26
申请号：US16708082
申请日：2019-12-09
申请人： NANTKWEST, INC.
IPC分类号： A61K35/17 , C07K14/725 , C07K14/705 , A61P35/02 , C07K14/55 , C12N15/85 , A61K9/00 , C07K14/54 , C07K14/82 , C12N15/62
摘要： Provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) a homing receptor, ii) Antigen Binding Protein (ABP) or Chimeric Antigen Receptor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Further provided herein are modified NK-92® cells comprising one or more nucleic acids encoding i) IL-12 and/or TGF-beta trap, ii) an Antigen Binding Protein (ABP) or Chimeric Antigen Receptor (CAR) that specifically binds to a target antigen, iii) an Fc Receptor such as CD16 or CD16-158V, and/or iv) a cytokine, wherein the nucleic acid sequence is operably linked to a promoter. Also provided are compositions and kits comprising the modified NK-92® cells, as well as methods of treating cancer using the modified cells.
-
公开(公告)号：US10563210B2
公开(公告)日：2020-02-18
申请号：US15523290
申请日：2015-05-13
发明人： Sang-Ki Rhee , Eun O Park , Hoon Seo , Guang Jin Choi , Keon-Hyoung Song
IPC分类号： C12N15/85 , C12N15/81 , C12P21/02 , C07K14/55 , C07K14/765
摘要： The present invention relates to a method for producing an interleukin-2 protein using methylotrophic yeast. The method for producing interleukin-2 according to the present invention shows high cell growth and protein synthesis rates by use of the established optimal cell line, and produces a large amount of a protein comprising interleukin-2 by use of the established optimal culture conditions utilizing methanol that is an inexpensive carbon source. In addition, the method according to the present invention isolates and purifies the protein by a simple process. Accordingly, the method according to the present invention highly pure interleukin-2, and thus has a significant effect on the mass-production of interleukin-2.
-
公开(公告)号：US20200024338A1
公开(公告)日：2020-01-23
申请号：US16476501
申请日：2018-01-11
摘要： R-spondin (RSPO) surrogate compositions and methods for their use are provided. RSPO surrogates of the invention comprise (i) a specific binding domain for Ring Finger Protein 43 (RNF43) or Zinc and Ring Finger Protein 3 (ZNRF3) and (ii) a cell targeting domain More specifically, wherein the specific binding domain for RNF43 or ZNRF3 is an antibody fragment, and wherein the cell targeting domain is a cytokine.
-
公开(公告)号：US20190352402A1
公开(公告)日：2019-11-21
申请号：US16414724
申请日：2019-05-16
发明人： Xiaoqiang KANG , Shoupeng LAI , Xiao HUANG
摘要： The present invention provides an isolated monoclonal antibody that specifically binds human PD-1. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule and a pharmaceutical composition comprising the antibody, as well as a diagnostic and treatment method using an anti-PD-1 antibody of the invention.
-
公开(公告)号：US20190330351A1
公开(公告)日：2019-10-31
申请号：US16311440
申请日：2017-06-20
申请人： KYMAB LIMITED
发明人： Jamie CAMPBELL , Nikole SANDY , Cassandra VAN KRINKS , Stephen John ARKINSTALL , Volker GERMASCHEWSKI , Ian KIRBY , Miha KOSMAC , Thomas GALLAGHER , Cecilia DEANTONIO , Stephen Douglas GILLIES
摘要： The present invention relates to anti-PD-L1 antibodies, bispecific antibodies containing one domain with specificity to PD-L1, and to immunocytokines comprising an anti-PD-L1 antibody fused to a cytokine, such as IL-2. The present invention also provides methods of treatment, uses and pharmaceutical compositions comprising the antibodies, bispecific antibodies and immunocytokines.
-
公开(公告)号：US20190322763A1
公开(公告)日：2019-10-24
申请号：US16215375
申请日：2018-12-10
申请人： Roche Glycart AG
发明人： Oliver AST , Peter BRUENKER , Thomas U. HOFER , Ralf HOSSE , Christian KLEIN , Ekkehard MOESSNER , Pablo UMANA
IPC分类号： C07K16/40 , C07K14/55 , A61K47/68 , C07K16/18 , C07K16/28 , C07K16/30 , C07K14/54 , A61K38/20 , C07K16/46
摘要： The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
-
公开(公告)号：US20190315883A1
公开(公告)日：2019-10-17
申请号：US16430301
申请日：2019-06-03
申请人： Roche Glycart AG
发明人： Oliver AST , Peter BRUENKER , Thomas U. HOFER , Ralf HOSSE , Christian Klein , Ekkehard MOESSNER , Pablo UMANA
IPC分类号： C07K16/40 , C07K14/55 , A61K47/68 , C07K16/18 , C07K16/28 , C07K16/30 , C07K14/54 , A61K38/20 , C07K16/46
摘要： The present invention generally relates to antigen-specific immunoconjugates for selectively delivering effector moieties that influence cellular activity. More specifically, the invention provides novel immunoconjugates comprising a first antigen binding moiety, an Fc domain and a single effector moiety. In addition, the present invention relates to polynucleotides encoding such immunoconjugates, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the immunoconjugates of the invention, and to methods of using these immunoconjugates in the treatment of disease.
-
-
-
-
-
-
-
-
-
搜索结果
1041 条记录 (耗时 0.057 秒)